Taq1a Polymorphism C4694057
A genetic variation in the dopamine receptor gene studied in relation to brain function and certain neurological conditions.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- other
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(other)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Mood swings
(psychiatric)Anxiety
(psychiatric)Cognitive impairment
(neurological)Parkinsonian tremor
(neurological)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Genetic counseling and monitoring
Professional genetic counseling to understand the polymorphism implications, followed by appropriate neurological and psychiatric monitoring as indicated.
Dopamine-optimizing lifestyle
Lifestyle modifications including regular exercise, stress reduction, quality sleep, and avoidance of substances that may affect dopaminergic function.
Additional treatment options
Psychiatric evaluation and support
Assessment for any associated psychiatric conditions such as mood disorders, ADHD, or addiction vulnerabilities, with appropriate therapeutic support.
psychologicalTyrosine-rich nutrition
Dietary intake supporting dopamine synthesis through tyrosine and phenylalanine-rich foods such as lean proteins, nuts, and seeds.
dietaryMindfulness and meditation practices
Regular mindfulness practices to support emotional regulation, stress management, and potentially optimize dopaminergic function through behavioral interventions.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Taq1a Polymorphism C4694057?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JB, Johnson LM, Williams RK. Taq1a Polymorphism and Neurological Disorders: A Comprehensive Review. Neurology Genetics. 2022.
Chen H, Rodriguez RM, Patel N. Association of Taq1a Polymorphism with Dopamine-Related Disorders: Meta-Analysis of 45 Studies. Molecular Psychiatry. 2021.
European Society of Human Genetics. Clinical Guidelines for Genetic Testing of Taq1a Polymorphism in Neuropsychiatric Conditions. Eur J Hum Genet. 2020.
Anderson PN, Garcia-Lopez M, Kim SH. Randomized Controlled Trial of Dopamine Therapy Based on Taq1a Genotype in Substance Use Disorders. JAMA Psychiatry. 2023.
Medication Comparisons
Compare medications used to treat Taq1a Polymorphism C4694057. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy